Sarepta Therapeutics (SRPT) EBT Margin (2012 - 2026)

Sarepta Therapeutics' EBT Margin history runs 13 years deep, the most recent figure standing at 85.73% for Q1 2026.

• In Q1 2026, EBT Margin rose 37337.0% year-over-year to 85.73%; the TTM figure through Mar 2026 stood at 1.32% (up 1712.0% YoY), while the FY2025 annual figure was 31.94%, down 4081.0% from the prior year.
• EBT Margin was 85.73% for Q1 2026 at Sarepta Therapeutics, up from 62.83% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 199.35% in Q4 2022 to a low of 473.28% in Q1 2022.
• Historically, EBT Margin has averaged 57.53% across 5 years, with a median of 10.0% in 2023.
• The sharpest annual moves came in 2022 and 2026: EBT Margin plunged 35936 bps in 2022, then surged 37337 bps in 2026.
• A 5-year view of EBT Margin shows it stood at 199.35% in 2022, then plunged by 70 bps to 60.2% in 2023, then tumbled by 80 bps to 12.1% in 2024, then sank by 619 bps to 62.83% in 2025, then surged by 236 bps to 85.73% in 2026.
• The last three EBT Margin figures came in at 85.73% (Q1 2026), 62.83% (Q4 2025), and 48.59% (Q3 2025), per Business Quant data.